Placebos
Phase
Phase2Study status
CompletedView details
Viking Therapeutics, Inc.
IndicationNASH - Nonalcoholic Steatohepatitis
Actual study completion2024-01-26
Cash and cash equivalents · Restricted cash and marketable securities excluded
Cash verified Nov 16, 2026
No verified development in tracked sources.
Next verified event · Clinical readout window
Announced Oct 28, 2026 · Announced window
Official announcementparticipants will receive initial weekly subcutaneous doses of VK2735 for 21 weeks. Following Week 21, participants will transition to a range of VK2735 maintenance dosing options including daily oral doses, monthly subcutaneous doses, every-other-week subcutaneous doses, or placebo. Study objectives are to evaluate the safety, tolerability, and pharmacokinetic profile of VK2735 under these various dosing regimens. Exploratory endpoints will assess changes in body weight from baseline and from Week 21 to the end of the study at Week 33. The company expects the results from Part 2 of this study to be available in 2027.
Clinical readout window
Announced Oct 28, 2026 · Announced window
Official announcementVANQUISH Extension Studies to Commence in 1Q27. Following completion of the 78-week treatment period in both VANQUISH studies, participants are eligible to enroll in extension studies, enabling them to continue their treatment for up to an additional 52 weeks. The extension studies will provide important long-term safety and efficacy data and afford subjects the opportunity to continue receiving VK2735 upon completion of the primary dosing periods. In addition, the VANQUISH-1 extension study will include certain less-frequent dosing regimens, including every-other-week and monthly administration. The company anticipates the results of the extension studies to be available in 2028.
8 programs · 13 verified studies
| Company | Drug | Indication | Phase | Study status | Timing | Registry |
|---|---|---|---|---|---|---|
| VKTX Viking Therapeutics, Inc. | Placebos | NASH - Nonalcoholic Steatohepatitis | Phase2 | Completed | Actual study completion2024-01-26 | NCT04173065 |
| VKTX Viking Therapeutics, Inc. | SC VK3019 | Obese Adults | Phase1 | Recruiting | Estimated study completion2026-11 | NCT07846033 |
| VKTX Viking Therapeutics, Inc. | VK0214 | Adrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy (X-ALD) | Phase1 | Completed | Actual study completion2024-11-08 | NCT04973657 |
| VKTX Viking Therapeutics, Inc. | VK2735 | Weight Loss; NASH | Phase1 | Completed | Actual study completion2024-12-03 | NCT05203237 |
| VKTX Viking Therapeutics, Inc. | VK2735 | Weight Loss | Phase2 | Completed | Actual study completion2024-04-02 | NCT06068946 |
| VKTX Viking Therapeutics, Inc. | VK2735 | Weight Loss | Phase2 | Completed | Actual study completion2025-08-15 | NCT06828055 |
| VKTX Viking Therapeutics, Inc. | VK2735 | Weight Loss | Phase3 | Active not recruiting | Estimated study completion2027-08-01 | NCT07104383 |
| VKTX Viking Therapeutics, Inc. | VK2735 | Weight Loss | Phase3 | Active not recruiting | Estimated study completion2027-08-01 | NCT07104500 |
| VKTX Viking Therapeutics, Inc. | VK2735 | Weight Loss | Phase3 | Not yet recruiting | Estimated study completion2028-08 | NCT07868835 |
| VKTX Viking Therapeutics, Inc. | VK2735 Drug | Weight Loss; NASH | Phase1 | Completed | Actual study completion2024-12-03 | NCT05203237 |
Phase
Phase2Study status
CompletedViking Therapeutics, Inc.
IndicationNASH - Nonalcoholic Steatohepatitis
Actual study completion2024-01-26
Phase
Phase1Study status
RecruitingViking Therapeutics, Inc.
IndicationObese Adults
Estimated study completion2026-11
Phase
Phase1Study status
CompletedViking Therapeutics, Inc.
IndicationAdrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy (X-ALD)
Actual study completion2024-11-08
Phase
Phase1Study status
CompletedViking Therapeutics, Inc.
IndicationWeight Loss; NASH
Actual study completion2024-12-03
Phase
Phase2Study status
CompletedViking Therapeutics, Inc.
IndicationWeight Loss
Actual study completion2024-04-02
Phase
Phase2Study status
CompletedViking Therapeutics, Inc.
IndicationWeight Loss
Actual study completion2025-08-15
Phase
Phase3Study status
Active not recruitingViking Therapeutics, Inc.
IndicationWeight Loss
Estimated study completion2027-08-01
Phase
Phase3Study status
Active not recruitingViking Therapeutics, Inc.
IndicationWeight Loss
Estimated study completion2027-08-01
Phase
Phase3Study status
Not yet recruitingViking Therapeutics, Inc.
IndicationWeight Loss
Estimated study completion2028-08
Phase
Phase1Study status
CompletedViking Therapeutics, Inc.
IndicationWeight Loss; NASH
Actual study completion2024-12-03
0 unverified sponsor matches remain unlinked.
No verified developments in tracked sources.